your badges 52W Range $1–$12 0% of range Analyst Rating STRONG BUY 7 analysts Price Target $9 +1339% upside P/E -22700.0 ROE -64.7% Net Profit Margin ·

BDRX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $0.62
P/E -22700.0
EPS $-0.00
ROE -64.7%
52W Range $1–$12

BDRX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 8
Ex-date Split Type
April 6, 2026 1-for-5 Reverse
July 31, 2025 1-for-10 Reverse
Oct. 4, 2024 1-for-25 Reverse
July 5, 2023 1-for-80 Reverse
March 27, 2023 1-for-4 Reverse
Sept. 26, 2022 1-for-5 Reverse
March 3, 2020 1-for-5 Reverse
April 8, 2019 1-for-10 Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue·
2016-12-31 → 2023-12-31
EPS$-0.00
2022-12-31 → 2025-12-31
Free Cash Flow$-6M
2017-12-31 → 2025-12-31
Net margin·
2017-12-31 → 2023-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend BDRX 5Y avg Peer Median Verdict
P/E -22700.05Y avg ≈-36884.7 ≈-36884.7 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 14
Metric Trend 2025202420232022202120202019201820172016
Revenue ··$381.0K$699.0K$578.0K$343.0K$674.0K$2M$989.0K$1M
Cost of Revenue ········$926.0K$667.0K
Gross Profit ········$7M$6M
R&D Expense $4M$5M$4M$5M$5M$6M$8M$9M$8M$8M
Operating Income $-9M$-9M$-8M$-9M$-7M$-23M$-11M$-12M$-13M$-10M
Interest Expense $229.0K$165.0K$41.0K$53.0K$44.0K$431.0K$97.0K$587.0K$166.0K$73.0K
Interest Income $2M$3M$570.0K$497.0K$936.0K$1.0K$492.0K$2.0K$415.0K$1M
Pretax Income $-6M$-6M$-7M$-8M$-6M$-23M$-11M$-12M$-13M$-8M
Income Tax $-105.0K$-250.0K$-406.0K$-832.0K$-646.0K$-1M$2M$-2M$-1M$-2M
Net Income $-6M$-6M$-7M$-8M$-5M$-22M$-10M$-15M$-16M$-20M
EPS (Basic) $-0.00$-0.00$-0.02$-1.55······
EPS (Diluted) $-0.00$-0.00$-0.02$-1.55······
Shares (Basic) 54,861,066,2644,952,784,179315,849,6004,941,7934,027,3452,142,00018,330,5883,056,3032,565,86636,072,752
EBITDA $-9M$-9M$-8M$-9M$-7M$-23M$-11M$-12M$-18M·
Balance Sheet 13
Metric Trend 2025202420232022202120202019201820172016
Cash & Equivalents $9M$2M$6M$3M$9M$8M$11M$2M$13M$18M
Receivables $4M$7M$637.0K$1M$1M$572.0K$992.0K$1M$3M$2M
Inventory ········$941.0K$817.0K
Current Assets $12M$9M$7M$5M$12M$9M$14M$6M$19M$22M
PP&E (Net) $91.0K$324.0K$571.0K$831.0K$1M$542.0K$2M$2M$3M$3M
Goodwill ·····$0$2M$2M$13M·
Intangibles ·····$0$10M$10M$10M·
Total Assets $18M$15M$11M$6M$13M$10M$31M$20M$49M$57M
Accounts Payable $3M$4M$1M$1M$1M$1M$4M$2M$8M$8M
Current Liabilities $6M$5M$6M$2M$2M$3M$6M$2M$8M$9M
Total Liabilities $7M$6M$6M$2M$2M$3M$11M$4M$15M$11M
Retained Earnings $-156M$-150M$-145M$-135M$-128M$-122M$-100M$-90M$-75M$-59M
Stockholders' Equity $11M$8M$5M$3M$10M$7M$20M$17M$35M$46M
Cash Flow 6
Metric Trend 2025202420232022202120202019201820172016
Operating Cash Flow $-6M$-12M$-7M$-7M$-6M$-9M$-6M$-13M$-13M$-13M
CapEx $2.0K$9.0K$26.0K$62.0K$320.0K$209.0K$310.0K$244.0K$707.0K$1M
Investing Cash Flow $-583.0K$-598.0K$-265.0K$-220.0K$-278.0K$3M$-4M$9M$-1M$-1M
Financing Cash Flow $13M$9M$10M$47.0K$9M$3M$19M$-6M$10M$15M
Free Cash Flow $-6M$-12M$-7M$-7M$-6M$-10M$-7M$-14M$-14M·
Levered FCF $-6M$-12M$-7M$-7M$-6M$-10M$-7M$-14M$-14M·
Profitability 8
Metric Trend 2025202420232022202120202019201820172016
Gross Margin ········87.8%·
Operating Margin ··-2103.4%-1277.8%-1210.7%-6717.2%-1679.2%-609.6%-231.3%·
Net Margin ··-1858.0%-1095.3%-944.6%-6469.1%-1496.3%-775.5%-211.4%·
Pretax Margin ··-1964.6%-1214.3%-1056.4%-6842.6%-1620.6%-639.8%-228.1%·
EBITDA Margin ··-2103.4%-1277.8%-1210.7%-6717.2%-1679.2%-609.6%-231.3%·
ROA -38.7%-45.2%-88.1%-83.0%-48.0%-109.0%-39.3%-43.1%-30.3%·
ROE -64.7%-88.1%-180.6%-112.5%-63.6%-168.9%-55.3%-58.3%-40.0%·
ROIC -74.6%-105.9%-162.0%-254.8%-74.0%-324.2%-48.4%-58.4%-47.0%·
Liquidity & Solvency 3
Metric Trend 2025202420232022202120202019201820172016
Current Ratio 2.01.81.32.56.43.12.42.32.2·
Quick Ratio 2.01.61.22.05.62.72.11.52.0·
Interest Coverage -37.8-55.8-195.5-168.5-159.0-53.5-116.7-20.1-105.9·
Efficiency 3
Metric Trend 2025202420232022202120202019201820172016
Asset Turnover ··0.00.10.10.00.00.10.1·
Inventory Turnover ········1.1·
Receivables Turnover ··0.50.70.70.40.50.82.7·
Per Share 1
Metric Trend 2025202420232022202120202019201820172016
EPS (TTM) $-0.00$-0.00$-0.02$-1.55······
Valuation (TTM) 4
Metric Trend 2025202420232022202120202019201820172016
Revenue TTM ··$381.0K$699.0K$578.0K$343.0K$674.0K$2M$989.0K·
Net Income TTM $-6M$-6M$-7M$-8M$-5M$-22M$-10M$-15M$-16M·
P/E -22700.0-40500.0-33500.0-50838.7······
Earnings Yield 0.00%0.00%0.00%0.00%······

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue · · $381.0K $699.0K $578.0K
Operating Margin % · · -2103.4% -1277.8% -1210.7%
Net Income $-6M $-6M $-7M $-8M $-5M
Diluted EPS $-0.00 $-0.00 $-0.02 $-1.55 ·

Institutional owners (13F) 1 filer · $8 total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 1
Value held $8
New positions 0
Exited positions 6
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
0 6 0 1 ·

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.

Institution Value Shares % of tracked 13F Type
RHUMBLINE ADVISERS $8 3 100.00% Shares

Activists & 5%+ owners 1 position

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
China Medical System Holdings Limited, CMS Medical Venture Investment (HK) Limited, A&B (HK) COMPANY LIMITED, A&B Brother Limited, Dr. Lam Kong April 4, 2019 · Initial filing Board campaign SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

BDRX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 7 analysts BUY
Median target $8.92 +1339.2%
3 42.9% Strong Buy
3 42.9% Buy
1 14.3% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

1 analysts · 2026-09-28

Mean target $8.92 +1339.2%

Low$8.92 Mean$8.92 High$8.92

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
BDRX · -22700.0 · · -64.7% ·
ROIV $19.95B -51.3 -71.6% -3629.2% -6.5% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 20-F filed Mar 27, 2026